Whole-Tumor-Cell Vaccines

  • Timothy M. Clay
  • Paul J. Mosca
  • H. Kim Lyerly
  • Michael A. Morse
Part of the Cancer Drug Discovery and Development book series (CDD&D)


Although identification of tumor antigens has propelled the development of many different approaches to cancer immunotherapy, whole-tumor vaccines continue to be of interest because they contain a large number of antigens, known and unknown, allowing for both widely applicable as well as patient-specific vaccines. Although the presence of a progressing tumor might suggest that whole-tumor cells would not be immunogenic, mouse experiments performed 60 yr ago first demonstrated that tumor cells could elicit immunity and protect syngeneic mice from a subsequent tumor challenge (1,2). In fact, in one model, cell-associated antigen was associated with better presentation of antigen to CD8 T cells than soluble antigen (3). Thus, it is clear that how the immunizations are performed or how modifications are made to the tumor to increase immunogenicity are important for activation of tumor-abrogating immune responses. For example, tumor cells may be injected along with potent inflammatory adjuvants or they may be genetically altered to express cytokines, human leulcocyte antigen (HLA) or costimulatory molecules. This chapter will discuss the scientific basis for whole-cell vaccines, whereas others will discuss cytokine-modified tumor-cell vaccines, haptenated tumors, tumorcell lysates, or shed tumor cell antigens.


Danger Signal Costimulatory Molecule Syngeneic Mouse Murine Melanoma Model Secondary Lymphatic Organ 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Gross L. Intradermal immunization of C3H mice against a sarcoma that originated in an animal of the same line. Cancer Res 1943;3:326–333.Google Scholar
  2. 2.
    Prehn RT, Main LT. Immunity to methylcholanteren-induced sarcomas. J Natl Cancer Inst 1957;18:769.PubMedGoogle Scholar
  3. 3.
    Li M, Davey GM, Sutherland RM, Kurts C, Lew AM, Hirst C, et al. Cell-associated ovalbumin is crosspresented much more efficiently than soluble ovalbumin in vivo. J Immunol 2001;166:6099–6103.PubMedGoogle Scholar
  4. 4.
    Ochsenbein AF, Sierro S, Odermatt B, Pericin M, Karrer U, Hermans J, et al. Roles of tumour localization,second signals and cross priming in cytotoxic T-cell induction. Nature 2001;411: 1058–1064.PubMedCrossRefGoogle Scholar
  5. 5.
    Wolkers MC, Stoetter G,Vyth-Dreese FA, Schumacher TN. Redundancy of direct priming and crosspriming in tumor-specific CD8(+)T cell responses. J Immunol 2001;167:3577–3584.PubMedGoogle Scholar
  6. 6.
    van Elsas A, Sutmuller RP, Hurwitz AA, Ziskin J, Villasenor J, Medema JP, et al. Elucidating the autoimmune and anti-tumor effector mechanisms of a treatment based on cytotoxic T lymphocyte antigen-4 blockade in combination with a B16 melanoma vaccine:comparison of prophylaxis and therapy. J Exp Med 2001;194:481–489.PubMedCrossRefGoogle Scholar
  7. 7.
    Hanna MG Jr, Peters LC. Immunotherapy of established micrometastases with Bacillus CalmetteGuerin tumor cell vaccine. Cancer Res. 1978;38:204–209.PubMedGoogle Scholar
  8. 8.
    Ward S, Casey D, Labarthe MC, Whelan M, Dalgleish A, Pandha H, Todryk S. Immunotherapeutic potential of whole tumour cells. Cancer Immunol Immunother. 2002;51:351–357.PubMedCrossRefGoogle Scholar
  9. 9.
    Todryk SM, Birchall LJ, Erlich R, Halanek N, Orleans-Lindsay JK, Dalgleish AG. Efficacy of cytokine gene transfection may differ for autologous and allogeneic tumour cell vaccines. Immunology. 2001;102: 190–198.PubMedCrossRefGoogle Scholar

Copyright information

© Humana Press Inc. 2004

Authors and Affiliations

  • Timothy M. Clay
  • Paul J. Mosca
  • H. Kim Lyerly
  • Michael A. Morse

There are no affiliations available

Personalised recommendations